In my first Seeking Alpha article about Zogenix (NASDAQ:ZGNX), I outlined a potential pathway and precedent for the FDA to withdraw the marketing approval for Zogenix's Zohydro. For a full discussion of how I was not advocating for the drug's life in either direction you can check the comments, however; the point was purely that the FDA removed Oxycontin from the market to replace it with an abuse deterrent version. I was pointing out that the agency could do that again.
Over the past few months the FDA has come out and made a rather unprecedented, in my opinion, public effort to affirm their approval decision. FDA Commissioner Margaret Hamburg has blogged about her views on the drug...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|